Vials labelled"COVID-19 Coronavirus Vaccine" and a syringe are seen in front of the Novavax logo in this illustration. WASHINGTON: Novavax on Monday reported late-stage data from its United States-based clinical trial showing that its vaccine is more than 90 per cent effective against COVID-19 across a variety of variants of the virus.
Protein-based vaccines are a conventional approach that use purified pieces of the virus to spur an immune response. Vaccines against whooping cough and shingles employ this approach. Novavax also detected variants of COVID-19 first found in Brazil, South Africa and India among its trial participants, Novavax's head of research and development, Dr Gregory Glenn, told Reuters.The vaccine was 91 per cent effective among volunteers at high risk of severe infection and 100 per cent effective in preventing moderate and severe cases of COVID-19. It was roughly 70 per cent effective against COVID-19 variants that Novavax was unable to identify, Glenn said.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »